ALPK1 agonists ignite innate immunity in anticancer therapy
A recent study published in Nature by Tian et al. identifies UDSP-Hep as a synthetic agonist of the innate immune receptor Alpha-protein kinase 1 (ALPK1) that induces enhanced antitumor activity compared with the canonical ALPK1 agonist ADP-Hep and Toll-like receptor or stimulator of interferon genes agonists. UDSP-Hep drives the tumor microenvironment toward a proinflammatory, antitumor state.
Authors
- Si Ming Man (ORCID: https://orcid.org/0000-0002-5079-2857)
- Shreya Mahajan
- Harrison Bazley
Institutions
- Australian National University (AU)
Publication Details
- Journal
- Trends in cancer
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1016/j.trecan.2026.01.013
- Primary Topic
- Immune Response and Inflammation
- Type
- article
- Field-Weighted Citation Impact
- 0.00